Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS)

Next Previous
Search
Trial Profile

A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMCY-0141 (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ISEMIS Study
  • Sponsors ImCyse

Most Recent Events

  • 07 Mar 2024 Status changed from recruiting to active, no longer recruiting.
  • 19 Apr 2022 New trial record
  • 13 Apr 2022 According to Imcyse media release, first patient has been dosed in this trial;

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top